瑞銀:升融創中國(1918.HK)評級至“買入” 目標價升至60.8港元
瑞銀髮布報告稱,上調融創中國(1918.HK)目標價及評級,由“沽售”越級升至“買入”,目標價由27.1港元急升至60.8港元,上調幅度1.24倍。
該行稱,對融創轉為樂觀,主要因為內房的融資放鬆,現轉為看好融創收購土地能力,特別是收購內房商以及拓展文化旅遊項目,獲當地政府歡迎。
該行表示,融創在2019年下半年土地收購放慢,令負債比率在2019年底降至150%,故上調2019-2021年對融創的盈利預測8%-13%,以反映併合業務的重估盈利收益攤銷,以及未來項目入賬的調整。調整後,該行預測高於同業約4%-7%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.